TrialJAMA network open2023

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.

Matthew D Sims et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.